Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?

Leukemia & lymphoma - 1 Dec 2014

Pardanani Animesh, Tefferi Ayalew

Abstract excerpt

Current data suggest that constitutively active JAK-STAT signaling plays a central role in the pathogenesis of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), regardless of the specific underlying molecular abnormality. This observation provides strong rationale for use of JAK inhibitors for MPN treatment, and these drugs were first tested in myelofibrosis (MF) patients. Ruxolitinib, a JAK-1/2 inhibitor,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Janus Kinases
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Receptors, Colony-Stimulating Factor

Share to STAT Transcription Factors

Source

Identifiers

PMID: 25520049
DOI: 10.3109/10428194.2014.985159

Genes

ABL1
BCR
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?PMID 25520049Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.Semantic proximity Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Semantic proximity Read ↗

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.Semantic proximity Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

Targeting myeloproliferative neoplasms with JAK inhibitors.Semantic proximity Read ↗

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibitors: what's the true therapeutic potential?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.